Sanctuary Advisors LLC Grows Position in Insulet Co. (NASDAQ:PODD)

Sanctuary Advisors LLC increased its holdings in shares of Insulet Co. (NASDAQ:PODD) by 8.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,401 shares of the medical instruments supplier’s stock after buying an additional 350 shares during the period. Sanctuary Advisors LLC’s holdings in Insulet were worth $1,232,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Blue Trust Inc. lifted its position in shares of Insulet by 84.1% during the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 58 shares in the last quarter. Venturi Wealth Management LLC lifted its position in shares of Insulet by 633.3% during the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock valued at $36,000 after buying an additional 133 shares in the last quarter. TD Private Client Wealth LLC lifted its position in shares of Insulet by 32.6% during the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock valued at $53,000 after buying an additional 56 shares in the last quarter. Friedenthal Financial purchased a new position in shares of Insulet during the 4th quarter valued at approximately $57,000. Finally, Versant Capital Management Inc lifted its position in shares of Insulet by 106.1% during the 4th quarter. Versant Capital Management Inc now owns 305 shares of the medical instruments supplier’s stock valued at $80,000 after buying an additional 157 shares in the last quarter.

Analyst Ratings Changes

Several research analysts recently commented on the company. Piper Sandler increased their price objective on Insulet from $285.00 to $310.00 and gave the company an “overweight” rating in a research note on Friday, February 21st. Stifel Nicolaus increased their price objective on Insulet from $245.00 to $293.00 and gave the company a “hold” rating in a research note on Friday, February 21st. Citigroup increased their price objective on Insulet from $310.00 to $355.00 and gave the company a “buy” rating in a research note on Friday, February 21st. Morgan Stanley increased their price objective on Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a research note on Monday, November 11th. Finally, Wells Fargo & Company raised their target price on Insulet from $305.00 to $322.00 and gave the stock an “overweight” rating in a research note on Friday, February 21st. Three investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $289.06.

Insulet Stock Down 5.9 %

Insulet stock opened at $266.68 on Wednesday. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. Insulet Co. has a 1-year low of $160.19 and a 1-year high of $289.46. The company has a market cap of $18.71 billion, a PE ratio of 46.06, a price-to-earnings-growth ratio of 3.62 and a beta of 1.23. The stock’s 50 day moving average price is $273.40 and its 200 day moving average price is $249.05.

Insulet (NASDAQ:PODD) last posted its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.00 by $0.15. The company had revenue of $597.50 million for the quarter, compared to the consensus estimate of $582.02 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. On average, sell-side analysts predict that Insulet Co. will post 3.92 EPS for the current fiscal year.

Insider Activity

In related news, CAO Lauren Budden sold 915 shares of the company’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total value of $252,192.30. Following the completion of the transaction, the chief accounting officer now directly owns 5,733 shares in the company, valued at approximately $1,580,129.46. This represents a 13.76 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Eric Benjamin sold 12,394 shares of the company’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the transaction, the executive vice president now owns 11,383 shares of the company’s stock, valued at $3,187,240. The trade was a 52.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.47% of the company’s stock.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.